Table 1.

Numbers of individuals (on nonplacebo dosages) and assay times of HIV RNA for each study

DrugnaAssay time point(s) (days)bNo. of CD4+ T cells/mm3d
Raltegravir2501/4, 1/2123479≥100
Rilpivirine360123456750–500
Abacavir1001237≥200
TDF1101237≥200
Enfuvirtide7c03710, 1423–774
Maraviroc6401/6, 1/3, 1/2123456789≥250
Nelfinavir701/6, 1/3, 1/21236913, 20, 27200–500
Ritonavir501/12, 1/6, 1/4, 1/2, 3/41, 5/4, 6/4, 7/42345672–412
  • a n, number of patients.

  • b Start of monotherapy in each case has been translated to day zero for consistency, and some time points are fractional. Not all patients were assayed at each time. Individuals were either antiretroviral naïve or were not taking antiretroviral drugs for periods prior to commencement of monotherapy.

  • c The enfuvirtide HIV RNA data consisted of data for four individuals in the 100-mg dosage group measured by PCR, as well as the mean data for each of the three dosage groups (3 mg, 10 mg, and 30 mg) measured by bDNA.

  • d Screening amount.